Journal Article
. 2020 Jul;14().
doi: 10.1177/1179554920931816.

Current State of the Art in the Adjuvant Systemic Treatment of Premenopausal Patients With Early Breast Cancer

Francesca Parisi 1 Maria Grazia Razeti 1 Eva Blondeaux 2 Luca Arecco 1 Marta Perachino 1 Marco Tagliamento 2 Alessia Levaggi 1 Piero Fregatti 3 Francesca Poggio 4 Matteo Lambertini 1 
Affiliations
  • PMID: 32647477
  •     90 References
  •     1 citations

Abstract

Breast cancer is the most frequent malignancy diagnosed in premenopausal women. In this age group, breast tumors tend to be diagnosed at more advanced stages and to harbor more aggressive biological features. In addition, specific age-related issues including genetic counseling, fertility preservation, impact on social and couple relationships, working life, and management of long-term side effects should be considered highly relevant when managing early breast cancer in premenopausal women. Therefore, the care of these patients is particularly complex and a multidisciplinary approach is mandatory. The present review summarizes the current state of art in the adjuvant systemic treatment of premenopausal women with early breast cancer focusing on the optimal chemotherapy, endocrine therapy, and targeted therapy approaches in this specific patient population.

Keywords: BRCA; Breast cancer; adjuvant; premenopausal; survivorship.

20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years.
Hongchao Pan, Richard Gray, +9 authors, EBCTCG.
N Engl J Med, 2017 Nov 09; 377(19). PMID: 29117498    Free PMC article.
Highly Cited.
Dose-dense FEC followed by docetaxel versus docetaxel plus cyclophosphamide as adjuvant chemotherapy in women with HER2-negative, axillary lymph node-positive early breast cancer: a multicenter randomized study by the Hellenic Oncology Research Group (HORG).
D Mavroudis, A Matikas, +10 authors, Breast Cancer Investigators of the Hellenic Oncology Research Group (HORG), Athens, Greece.
Ann Oncol, 2016 Aug 10; 27(10). PMID: 27502729
Diagnosis and Treatment of Breast Cancer in Young Women.
Lorenzo Rossi, Calogero Mazzara, Olivia Pagani.
Curr Treat Options Oncol, 2019 Nov 30; 20(12). PMID: 31776799
Review.
Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update on Ovarian Suppression.
Harold J Burstein, Christina Lacchetti, +9 authors, Jennifer J Griggs.
J Clin Oncol, 2016 Feb 18; 34(14). PMID: 26884586
Highly Cited. Systematic Review.
Seven-Year Follow-Up Analysis of Adjuvant Paclitaxel and Trastuzumab Trial for Node-Negative, Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer.
Sara M Tolaney, Hao Guo, +23 authors, Eric P Winer.
J Clin Oncol, 2019 Apr 03; 37(22). PMID: 30939096    Free PMC article.
Highly Cited.
Pathologic features and molecular phenotype by patient age in a large cohort of young women with breast cancer.
L C Collins, J D Marotti, +8 authors, A H Partridge.
Breast Cancer Res Treat, 2011 Nov 15; 131(3). PMID: 22080245
Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: american society of clinical oncology clinical practice guideline focused update.
Harold J Burstein, Sarah Temin, +10 authors, Jennifer J Griggs.
J Clin Oncol, 2014 May 29; 32(21). PMID: 24868023    Free PMC article.
Highly Cited.
The role of the addition of ovarian suppression to tamoxifen in young women with hormone-sensitive breast cancer who remain premenopausal or regain menstruation after chemotherapy (ASTRRA): study protocol for a randomized controlled trial and progress.
Hyun-Ah Kim, Sei Hyun Ahn, +37 authors, Woo Chul Noh.
BMC Cancer, 2016 May 21; 16. PMID: 27197523    Free PMC article.
Controversies about fertility and pregnancy issues in young breast cancer patients: current state of the art.
Matteo Lambertini, Oranite Goldrat, +2 authors, Ahmad Awada.
Curr Opin Oncol, 2017 May 04; 29(4). PMID: 28463857
Review.
Patient-reported outcomes with adjuvant exemestane versus tamoxifen in premenopausal women with early breast cancer undergoing ovarian suppression (TEXT and SOFT): a combined analysis of two phase 3 randomised trials.
Jürg Bernhard, Weixiu Luo, +18 authors, Barbara A Walley.
Lancet Oncol, 2015 Jun 21; 16(7). PMID: 26092816    Free PMC article.
Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials.
Early Breast Cancer Trialists' Collaborative Group (EBCTCG).
Lancet, 2019 Feb 12; 393(10179). PMID: 30739743    Free PMC article.
Highly Cited.
Platinum-based neoadjuvant chemotherapy in triple-negative breast cancer: a systematic review and meta-analysis.
F Poggio, M Bruzzone, +5 authors, M Lambertini.
Ann Oncol, 2018 Jun 07; 29(7). PMID: 29873695
Systematic Review.
Recent trends in breast cancer among younger women in the United States.
Louise A Brinton, Mark E Sherman, J Daniel Carreon, William F Anderson.
J Natl Cancer Inst, 2008 Nov 13; 100(22). PMID: 19001605    Free PMC article.
Dissecting the effect of hormone receptor status in patients with HER2-positive early breast cancer: exploratory analysis from the ALTTO (BIG 2-06) randomized clinical trial.
Matteo Lambertini, Christine Campbell, +15 authors, Evandro de Azambuja.
Breast Cancer Res Treat, 2019 May 28; 177(1). PMID: 31134488
Subtype-Dependent Relationship Between Young Age at Diagnosis and Breast Cancer Survival.
Ann H Partridge, Melissa E Hughes, +9 authors, Rulla M Tamimi.
J Clin Oncol, 2016 Aug 03; 34(27). PMID: 27480155
Highly Cited.
Absolute Improvements in Freedom From Distant Recurrence to Tailor Adjuvant Endocrine Therapies for Premenopausal Women: Results From TEXT and SOFT.
Olivia Pagani, Prudence A Francis, +13 authors, SOFT and TEXT Investigators and International Breast Cancer Study Group.
J Clin Oncol, 2019 Oct 17; 38(12). PMID: 31618131    Free PMC article.
Biology of breast cancer in young women.
Hatem A Azim, Ann H Partridge.
Breast Cancer Res, 2014 Dec 02; 16(4). PMID: 25436920    Free PMC article.
Highly Cited. Review.
Cancer incidence and mortality among young adults aged 20-39 years worldwide in 2012: a population-based study.
Miranda M Fidler, Sumit Gupta, +3 authors, Freddie Bray.
Lancet Oncol, 2017 Nov 08; 18(12). PMID: 29111259
Highly Cited.
Improving Adjuvant Endocrine Treatment Tailoring in Premenopausal Women With Hormone Receptor-Positive Breast Cancer.
Matteo Lambertini, Eva Blondeaux, Francesco Perrone, Lucia Del Mastro.
J Clin Oncol, 2019 Oct 17; 38(12). PMID: 31618128
Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Arlene Chan, Suzette Delaloge, +28 authors, ExteNET Study Group.
Lancet Oncol, 2016 Feb 15; 17(3). PMID: 26874901
Highly Cited.
Management of young women with early breast cancer.
Francesca Poggio, Matteo Lambertini, +6 authors, Lucia Del Mastro.
ESMO Open, 2018 Dec 19; 3(Suppl 1). PMID: 30559981    Free PMC article.
Cancer and fertility preservation: international recommendations from an expert meeting.
Matteo Lambertini, Lucia Del Mastro, +13 authors, Paola Anserini.
BMC Med, 2016 Jan 06; 14. PMID: 26728489    Free PMC article.
Highly Cited.
Absolute Benefit of Adjuvant Endocrine Therapies for Premenopausal Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer: TEXT and SOFT Trials.
Meredith M Regan, Prudence A Francis, +12 authors, Richard D Gelber.
J Clin Oncol, 2016 Apr 06; 34(19). PMID: 27044936    Free PMC article.
Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials.
Early Breast Cancer Trialists' Collaborative Group (EBCTCG), R Peto, +15 authors, K Pritchard.
Lancet, 2011 Dec 14; 379(9814). PMID: 22152853    Free PMC article.
Highly Cited.
Adjuvant ovarian suppression in premenopausal breast cancer.
Prudence A Francis, Meredith M Regan, +28 authors, International Breast Cancer Study Group.
N Engl J Med, 2014 Dec 17; 372(5). PMID: 25495490    Free PMC article.
Highly Cited.
Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer.
Stephen E Jones, Michael A Savin, +17 authors, Lina Asmar.
J Clin Oncol, 2006 Dec 01; 24(34). PMID: 17135639
Highly Cited.
What lies behind chemotherapy-induced amenorrhea for breast cancer patients: a meta-analysis.
Jianli Zhao, Jieqiong Liu, +8 authors, Fengxi Su.
Breast Cancer Res Treat, 2014 Mar 29; 145(1). PMID: 24671358
The prognostic performance of Adjuvant! Online and Nottingham Prognostic Index in young breast cancer patients.
Matteo Lambertini, Ana Catarina Pinto, +12 authors, Hatem A Azim.
Br J Cancer, 2016 Nov 02; 115(12). PMID: 27802449    Free PMC article.
Adding Ovarian Suppression to Tamoxifen for Premenopausal Breast Cancer: A Randomized Phase III Trial.
Hyun-Ah Kim, Jong Won Lee, +27 authors, Korean Breast Cancer Study Group.
J Clin Oncol, 2019 Sep 14; 38(5). PMID: 31518174
Adjuvant trastuzumab: a 10-year overview of its benefit.
Matteo Lambertini, Noam F Pondé, Cinzia Solinas, Evandro de Azambuja.
Expert Rev Anticancer Ther, 2016 Nov 25; 17(1). PMID: 27883296
Review.
Survival improvement in hormone-responsive young breast cancer patients with endocrine therapy.
Tae In Yoon, Ui-Kang Hwang, +8 authors, Hee Jeong Kim.
Breast Cancer Res Treat, 2017 Jun 12; 165(2). PMID: 28601930
Ovarian suppression using luteinizing hormone-releasing hormone agonists during chemotherapy to preserve ovarian function and fertility of breast cancer patients: a meta-analysis of randomized studies.
M Lambertini, M Ceppi, +9 authors, L Del Mastro.
Ann Oncol, 2015 Sep 09; 26(12). PMID: 26347105
Highly Cited. Review.
Multi-omics profiling of younger Asian breast cancers reveals distinctive molecular signatures.
Zhengyan Kan, Ying Ding, +20 authors, Yeon Hee Park.
Nat Commun, 2018 May 02; 9(1). PMID: 29713003    Free PMC article.
Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials.
Early Breast Cancer Trialists' Collaborative Group (EBCTCG).
Lancet Oncol, 2017 Dec 16; 19(1). PMID: 29242041    Free PMC article.
Highly Cited. Review.
Prognostic Impact of the 21-Gene Recurrence Score Assay Among Young Women With Node-Negative and Node-Positive ER-Positive/HER2-Negative Breast Cancer.
Philip D Poorvu, Shari I Gelber, +12 authors, Ann H Partridge.
J Clin Oncol, 2019 Dec 07; 38(7). PMID: 31809240    Free PMC article.
Adjuvant exemestane with ovarian suppression in premenopausal breast cancer.
Olivia Pagani, Meredith M Regan, +32 authors, International Breast Cancer Study Group.
N Engl J Med, 2014 Jun 03; 371(2). PMID: 24881463    Free PMC article.
Highly Cited.
Estimating the benefits of therapy for early-stage breast cancer: the St. Gallen International Consensus Guidelines for the primary therapy of early breast cancer 2019.
H J Burstein, G Curigliano, +11 authors, Members of the St. Gallen International Consensus Panel on the Primary Therapy of Early Breast Cancer 2019.
Ann Oncol, 2019 Aug 03; 30(10). PMID: 31373601
Highly Cited.
Frequency of Germline Mutations in 25 Cancer Susceptibility Genes in a Sequential Series of Patients With Breast Cancer.
Nadine Tung, Nancy U Lin, +6 authors, Judy E Garber.
J Clin Oncol, 2016 Mar 16; 34(13). PMID: 26976419    Free PMC article.
Highly Cited.
The prognostic effect of estrogen receptor status differs for younger versus older breast cancer patients.
Victoria Sopik, Ping Sun, Steven A Narod.
Breast Cancer Res Treat, 2017 Jun 12; 165(2). PMID: 28601929
Anthracycline and taxane-based chemotherapy versus docetaxel and cyclophosphamide in the adjuvant treatment of HER2-negative breast cancer patients: a systematic review and meta-analysis of randomized controlled trials.
Rafael Caparica, Marco Bruzzone, +3 authors, Matteo Lambertini.
Breast Cancer Res Treat, 2018 Nov 23; 174(1). PMID: 30465156
Systematic Review.
Dose-dense adjuvant chemotherapy in premenopausal breast cancer patients: A pooled analysis of the MIG1 and GIM2 phase III studies.
Matteo Lambertini, Marcello Ceppi, +20 authors, MIG and GIM study groups.
Eur J Cancer, 2016 Dec 13; 71. PMID: 27951450
BRCA1 and BRCA2 Mutation Testing in Young Women With Breast Cancer.
Shoshana M Rosenberg, Kathryn J Ruddy, +7 authors, Ann H Partridge.
JAMA Oncol, 2016 Feb 13; 2(6). PMID: 26867710    Free PMC article.
Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer.
Joseph A Sparano, Robert J Gray, +27 authors, George W Sledge.
N Engl J Med, 2018 Jun 05; 379(2). PMID: 29860917    Free PMC article.
Highly Cited.
Controversies in oncology: which adjuvant endocrine therapy is to be given to premenopausal patients with hormone receptor-positive breast cancer?
Matteo Lambertini, Giulia Viglietti, Evandro de Azambuja.
ESMO Open, 2018 Apr 11; 3(3). PMID: 29636992    Free PMC article.
Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: ASCO Clinical Practice Guideline Focused Update.
Harold J Burstein, Christina Lacchetti, +9 authors, Jennifer J Griggs.
J Clin Oncol, 2018 Nov 20; 37(5). PMID: 30452337
Highly Cited. Systematic Review.
Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozol plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12.
M Gnant, B Mlineritsch, +23 authors, Austrian Breast and Colorectal Cancer Study Group, Vienna, Austria.
Ann Oncol, 2014 Nov 19; 26(2). PMID: 25403582
Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial.
Miguel Martin, Frankie A Holmes, +32 authors, ExteNET Study Group.
Lancet Oncol, 2017 Nov 18; 18(12). PMID: 29146401
Highly Cited.
Anthracyclines in Early Breast Cancer: The ABC Trials-USOR 06-090, NSABP B-46-I/USOR 07132, and NSABP B-49 (NRG Oncology).
Joanne L Blum, Patrick J Flynn, +19 authors, Norman Wolmark.
J Clin Oncol, 2017 Apr 12; 35(23). PMID: 28398846    Free PMC article.
Highly Cited.
Twelve-Month Estrogen Levels in Premenopausal Women With Hormone Receptor-Positive Breast Cancer Receiving Adjuvant Triptorelin Plus Exemestane or Tamoxifen in the Suppression of Ovarian Function Trial (SOFT): The SOFT-EST Substudy.
Meritxell Bellet, Kathryn P Gray, +17 authors, Meredith M Regan.
J Clin Oncol, 2016 Jan 06; 34(14). PMID: 26729437    Free PMC article.
Docetaxel With Cyclophosphamide Is Associated With an Overall Survival Benefit Compared With Doxorubicin and Cyclophosphamide: 7-Year Follow-Up of US Oncology Research Trial 9735.
Stephen Jones, Frankie Ann Holmes, +17 authors, Michael A Savin.
J Clin Oncol, 2009 Feb 11; 27(8). PMID: 19204201
Highly Cited.
Impact of ovarian function suppression in premenopausal women with estrogen receptor-positive early breast cancer.
Matteo Lambertini, Giulia Viglietti, Evandro de Azambuja.
Curr Opin Oncol, 2018 Oct 10; 31(1). PMID: 30299291
Review.
Adjuvant Dose-Dense Chemotherapy for Breast Cancer: Available Evidence and Recent Updates.
Fernando Kude de Almeida, Daniela Dornelles Rosa.
Breast Care (Basel), 2019 Feb 26; 13(6). PMID: 30800040    Free PMC article.
Review.
Employment trends in young women following a breast cancer diagnosis.
Shoshana M Rosenberg, Ines Vaz-Luis, +8 authors, Ann H Partridge.
Breast Cancer Res Treat, 2019 May 31; 177(1). PMID: 31147983    Free PMC article.
The effects of paclitaxel, dose density, and trastuzumab on treatment-related amenorrhea in premenopausal women with breast cancer.
Mary E Abusief, Stacey A Missmer, +2 authors, Ann H Partridge.
Cancer, 2010 Jan 07; 116(4). PMID: 20052714
Risk of chemotherapy-induced amenorrhea in patients with breast cancer: a systematic review and meta-analysis.
A Zavos, A Valachis.
Acta Oncol, 2016 Apr 23; 55(6). PMID: 27105082
Systematic Review.
Adjuvant Anti-HER2 Therapy, Treatment-Related Amenorrhea, and Survival in Premenopausal HER2-Positive Early Breast Cancer Patients.
Matteo Lambertini, Christine Campbell, +19 authors, Evandro de Azambuja.
J Natl Cancer Inst, 2018 Jun 08; 111(1). PMID: 29878225    Free PMC article.
Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer.
Gunter von Minckwitz, Marion Procter, +16 authors, APHINITY Steering Committee and Investigators.
N Engl J Med, 2017 Jun 06; 377(2). PMID: 28581356    Free PMC article.
Highly Cited.
Phase III comparison of tamoxifen versus tamoxifen plus ovarian function suppression in premenopausal women with node-negative, hormone receptor-positive breast cancer (E-3193, INT-0142): a trial of the Eastern Cooperative Oncology Group.
Amye J Tevaarwerk, Molin Wang, +9 authors, Nicholas J Robert.
J Clin Oncol, 2014 Oct 29; 32(35). PMID: 25349302    Free PMC article.
Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer.
Gunter von Minckwitz, Chiun-Sheng Huang, +27 authors, KATHERINE Investigators.
N Engl J Med, 2018 Dec 06; 380(7). PMID: 30516102
Highly Cited.
Adjuvant Tamoxifen Plus Ovarian Function Suppression Versus Tamoxifen Alone in Premenopausal Women With Early Breast Cancer: Patient-Reported Outcomes in the Suppression of Ovarian Function Trial.
Karin Ribi, Weixiu Luo, +24 authors, Gini F Fleming.
J Clin Oncol, 2016 Mar 30; 34(14). PMID: 27022111    Free PMC article.
Gonadotropin-Releasing Hormone Agonists During Chemotherapy for Preservation of Ovarian Function and Fertility in Premenopausal Patients With Early Breast Cancer: A Systematic Review and Meta-Analysis of Individual Patient-Level Data.
Matteo Lambertini, Halle C F Moore, +18 authors, Lucia Del Mastro.
J Clin Oncol, 2018 May 03; 36(19). PMID: 29718793    Free PMC article.
Highly Cited. Systematic Review.
Incidence and Survival Among Young Women With Stage I-III Breast Cancer: SEER 2000-2015.
Alexandra Thomas, Anthony Rhoads, +7 authors, Paul A Romitti.
JNCI Cancer Spectr, 2019 Aug 09; 3(3). PMID: 31392297    Free PMC article.
ESO-ESMO 3rd international consensus guidelines for breast cancer in young women (BCY3).
Shani Paluch-Shimon, Olivia Pagani, +15 authors, Fatima Cardoso.
Breast, 2017 Aug 20; 35. PMID: 28822332
Highly Cited.
Post-neoadjuvant treatment and the management of residual disease in breast cancer: state of the art and perspectives.
Rafael Caparica, Matteo Lambertini, +3 authors, Martine Piccart.
Ther Adv Med Oncol, 2019 Mar 06; 11. PMID: 30833989    Free PMC article.
Review.
Early discontinuation of tamoxifen intake in younger women with breast cancer: is it time to rethink the way it is prescribed?
Laetitia Huiart, Anne-Déborah Bouhnik, +5 authors, Roch Giorgi.
Eur J Cancer, 2012 Apr 03; 48(13). PMID: 22464016
Selection of Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer: ASCO Clinical Practice Guideline Focused Update.
Neelima Denduluri, Mariana Chavez-MacGregor, +12 authors, Sharon H Giordano.
J Clin Oncol, 2018 May 23; 36(23). PMID: 29787356
Dose-Dense Chemotherapy: Principles, Clinical Results and Future Perspectives.
Marc L Citron.
Breast Care (Basel), 2008 Jan 01; 3(4). PMID: 21076605    Free PMC article.
Concurrent and sequential initiation of ovarian function suppression with chemotherapy in premenopausal women with endocrine-responsive early breast cancer: an exploratory analysis of TEXT and SOFT.
M M Regan, B A Walley, +15 authors, O Pagani.
Ann Oncol, 2017 Sep 16; 28(9). PMID: 28911092    Free PMC article.
Adjuvant zoledronic acid and letrozole plus ovarian function suppression in premenopausal breast cancer: HOBOE phase 3 randomised trial.
Francesco Perrone, Michelino De Laurentiis, +29 authors, Ciro Gallo.
Eur J Cancer, 2019 Jun 06; 118. PMID: 31164265
Clinical and Genomic Risk to Guide the Use of Adjuvant Therapy for Breast Cancer.
Joseph A Sparano, Robert J Gray, +27 authors, George W Sledge.
N Engl J Med, 2019 Jun 04; 380(25). PMID: 31157962    Free PMC article.
Highly Cited.
Differential impact of endocrine therapy and chemotherapy on quality of life of breast cancer survivors: a prospective patient-reported outcomes analysis.
A R Ferreira, A Di Meglio, +22 authors, I Vaz-Luis.
Ann Oncol, 2019 Oct 09; 30(11). PMID: 31591636
Prospective study of fertility concerns and preservation strategies in young women with breast cancer.
Kathryn J Ruddy, Shari I Gelber, +6 authors, Ann H Partridge.
J Clin Oncol, 2014 Feb 26; 32(11). PMID: 24567428    Free PMC article.
Highly Cited.
Dose-dense adjuvant chemotherapy in early breast cancer patients: 15-year results of the Phase 3 Mammella InterGruppo (MIG)-1 study.
Eva Blondeaux, Matteo Lambertini, +14 authors, Lucia Del Mastro.
Br J Cancer, 2020 Apr 02; 122(11). PMID: 32231293    Free PMC article.
Biomarker prediction of chemotherapy-related amenorrhea in premenopausal women with breast cancer participating in E5103.
Kathryn J Ruddy, Anne O'Neill, +7 authors, Ann H Partridge.
Breast Cancer Res Treat, 2014 Mar 04; 144(3). PMID: 24584876    Free PMC article.
Ovarian Suppression With Triptorelin During Adjuvant Breast Cancer Chemotherapy and Long-term Ovarian Function, Pregnancies, and Disease-Free Survival: A Randomized Clinical Trial.
Matteo Lambertini, Luca Boni, +14 authors, GIM Study Group.
JAMA, 2016 Jan 01; 314(24). PMID: 26720025
Impact of premenopausal status at breast cancer diagnosis in women entered on the placebo-controlled NCIC CTG MA17 trial of extended adjuvant letrozole.
P E Goss, J N Ingle, +11 authors, D Tu.
Ann Oncol, 2012 Oct 03; 24(2). PMID: 23028039    Free PMC article.
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis.
Patricia Cortazar, Lijun Zhang, +34 authors, Gunter von Minckwitz.
Lancet, 2014 Feb 18; 384(9938). PMID: 24529560
Highly Cited. Review.
Impact of Taxanes, Endocrine Therapy, and Deleterious Germline BRCA Mutations on Anti-müllerian Hormone Levels in Early Breast Cancer Patients Treated With Anthracycline- and Cyclophosphamide-Based Chemotherapy.
Matteo Lambertini, Nathalie Olympios, +8 authors, Florian Clatot.
Front Oncol, 2019 Jul 30; 9. PMID: 31355134    Free PMC article.
Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†.
F Cardoso, S Kyriakides, +6 authors, ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org.
Ann Oncol, 2019 Jun 05; 30(8). PMID: 31161190
Highly Cited.
Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy.
Norikazu Masuda, Soo-Jung Lee, +18 authors, Masakazu Toi.
N Engl J Med, 2017 Jun 01; 376(22). PMID: 28564564
Highly Cited.
Effect of age on breast cancer outcomes in women with human epidermal growth factor receptor 2-positive breast cancer: results from a herceptin adjuvant trial.
Ann H Partridge, Shari Gelber, +5 authors, Richard D Gelber.
J Clin Oncol, 2013 Jun 12; 31(21). PMID: 23752109
Differences in breast cancer incidence among young women aged 20-49 years by stage and tumor characteristics, age, race, and ethnicity, 2004-2013.
Meredith L Shoemaker, Mary C White, +2 authors, Isabelle Romieu.
Breast Cancer Res Treat, 2018 Feb 16; 169(3). PMID: 29445940    Free PMC article.
Germline BRCA mutation and outcome in young-onset breast cancer (POSH): a prospective cohort study.
Ellen R Copson, Tom C Maishman, +21 authors, Diana M Eccles.
Lancet Oncol, 2018 Jan 18; 19(2). PMID: 29337092    Free PMC article.
Highly Cited.
Higher incidence of premenopausal breast cancer in less developed countries; myth or truth?
Reza Ghiasvand, Hans-Olov Adami, +2 authors, Kazem Zendehdel.
BMC Cancer, 2014 Jun 03; 14. PMID: 24884841    Free PMC article.
Fertility concerns, preservation strategies and quality of life in young women with breast cancer: Baseline results from an ongoing prospective cohort study in selected European Centers.
M Ruggeri, E Pagan, +22 authors, O Pagani.
Breast, 2019 Jul 31; 47. PMID: 31362134
Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials.
Early Breast Cancer Trialists' Collaborative Group (EBCTCG), C Davies, +11 authors, R Peto.
Lancet, 2011 Aug 02; 378(9793). PMID: 21802721    Free PMC article.
Highly Cited.
Adjuvant Cyclophosphamide and Docetaxel With or Without Epirubicin for Early TOP2A-Normal Breast Cancer: DBCG 07-READ, an Open-Label, Phase III, Randomized Trial.
Bent Ejlertsen, Malgorzata K Tuxen, +16 authors, Henning T Mouridsen.
J Clin Oncol, 2017 Jul 01; 35(23). PMID: 28661759
Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2 × 2 factorial, randomised phase 3 trial.
Lucia Del Mastro, Sabino De Placido, +22 authors, Gruppo Italiano Mammella (GIM) investigators.
Lancet, 2015 Mar 06; 385(9980). PMID: 25740286
Predicting and communicating the risk of recurrence and death in women with early-stage breast cancer: a systematic review of risk prediction models.
Ellen G Engelhardt, Mirjam M Garvelink, +4 authors, Anne M Stiggelbout.
J Clin Oncol, 2013 Dec 18; 32(3). PMID: 24344212
Systematic Review.
Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer.
Prudence A Francis, Olivia Pagani, +34 authors, SOFT and TEXT Investigators and the International Breast Cancer Study Group.
N Engl J Med, 2018 Jun 05; 379(2). PMID: 29863451    Free PMC article.
Highly Cited.
Gender-specific aspects related to type of fertility preservation strategies and access to fertility care.
Marta Perachino, Claudia Massarotti, +6 authors, Matteo Lambertini.
ESMO Open, 2020 Oct 30; 5(Suppl 4). PMID: 33115753    Free PMC article.
Review.